SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
$9.36
arrow_upward
+2.41%(+0.22) 1D
$9.36
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 2, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SGIOY...
Open
$9.34
High
$9.39
Low
$9.32
Mkt. cap
2.65T
Avg. vol.
90.45K
Volume
48.04K
52-wk high
$12.00
52-wk low
$7.65
Beta
0.03
Shares outstanding
1.78B
No. of employees
6K
Open
$9.34
High
$9.39
Low
$9.32
Mkt. cap
2.65T
Avg. vol.
90.45K
Volume
48.04K
52-wk high
$12.00
52-wk low
$7.65
Beta
0.03
Shares outstanding
1.78B
No. of employees
6K
News stories
From web sources and news partners
AD HOC NEWS
·
1 day ago
Shionogi stock holds firm as Japanese pharma sector trades mixed
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
About Shionogi 2 ADR Representing 1 Ord Shs
CEOIsao Teshirogi
Employees6.22K
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com
AI content may include mistakes. Learn more